Research Paper Volume 16, Issue 8 pp 6954—6989
Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification
Figure 10. Prediction of the ceRNA network in glioma. (A, B) The regulating relationship of has-miR-103a-3p and LAPTM4A was investigated by a dual-luciferase reporter gene system. (C, D) Real-time qPCR was used to determine LAPTM4A mRNA levels in U251 cells. (E) The regulating relationship of has-miR-103a-3p and FGD5-AS1 was investigated by a dual-luciferase reporter gene system. (F) RNA-pull down assay was performed to detect has-miR-103a-3p enrichment in FGD5-AS1. (G) Western blotting assay was performed to detect LAPTM4A expression levels in the control and FGD5-AS1 group. (H) Western blotting assay was performed to detect LAPTM4A expression levels in the control, FGD5-AS1, and has-miR-103a-3p group. (I) Transwell assay was used to detect U251 cell metastasis in the control, FGD5-AS1, inh-NC, and inh-has-miR-103a-3p group. *p < 0.05, **p < 0.01.